If You Invested in Enzo Biochem Inc (ENZ)

Enzo Biochem, Inc. (historically traded under the symbol ENZ and later ENZB) is a life sciences company whose primary business is conducted through its Life Sciences division, Enzo Life Sciences. According to the company’s public disclosures, Enzo has operated as a life sciences company for over 45 years and has focused on labeling and detection technologies from DNA to whole cell analysis. Its activities are described in the Professional, Scientific, and Technical Services sector, with a focus on tools that support biomedical research and translational science.

The company’s Life Sciences division is centered on labeling and detection technologies that span DNA to whole cell analysis. Enzo reports that it offers a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins. These proprietary products and technologies are described as playing central roles in translational research and drug development areas such as cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry.

Enzo Biochem has characterized itself in multiple releases as a pioneer in molecular diagnostics, contributing to healthcare through technical platforms and reagent sets that support a diverse range of biomedical research and translational science needs. The company’s Life Sciences division supports the work of research centers and industry partners by manufacturing and supplying its product portfolio. Enzo also states that it has a broad and deep intellectual property portfolio, with patent coverage across many enabling technologies.

Business focus and operating model

Based on the company’s own descriptions, Enzo’s current core business is its Life Sciences division following its exit from the clinical lab business. The division is described as a focused manufacturer of a broad portfolio of life science tools aligned with market segments that include drug development and cell and gene therapy. Enzo has highlighted that its products are used by drug developers and that it has comprehensive manufacturing capabilities in the United States and Europe, which it views as important for its position in the life sciences tools market.

The company states that it monetizes its technology primarily via sales through a global distribution network and licensing. This means its revenue is tied to the sale of its life science tools and reagents, as well as licensing of proprietary technologies. Enzo has also emphasized product life cycle maintenance, including the removal of non-performing SKUs and the launch of new products to bolster its base business.

Product and technology portfolio

Enzo’s disclosures consistently reference a product portfolio that includes:

• Antibodies
• Genomic probes
• Assays
• Biochemicals
• Proteins

These products are positioned as tools that support cell biology, genomics, immunohistochemistry, small molecule chemistry, and broader translational research and drug development efforts. The company has also referred to technical platforms and reagent sets that support biomedical research and translational science needs, and to ongoing product launches and SKU expansion as part of its growth efforts.

Strategic developments and corporate status

Enzo Biochem has undergone significant corporate changes. In an 8-K dated June 24, 2025, the company disclosed that it entered into an Agreement and Plan of Merger with Bethpage Parent, Inc. and Bethpage Merger Sub, Inc., pursuant to which Merger Sub would merge with and into Enzo, with Enzo surviving as a wholly owned subsidiary of Parent. A subsequent 8-K dated August 19, 2025 reported that shareholders approved the merger proposal at a special meeting.

An 8-K dated August 20, 2025 states that on that date Merger Sub merged with and into Enzo Biochem, Inc., with Enzo surviving the merger as a wholly owned subsidiary of Bethpage Parent, Inc. The filing explains that each share of Enzo common stock issued and outstanding immediately prior to the effective time of the merger was converted into the right to receive cash consideration, and that as a result of the merger, Enzo’s common stock ceased trading on the OTCQX tier of the OTC Markets prior to the opening of trading on August 20, 2025.

On the same date, Enzo filed a Form 15 (Form 15-12G) certifying the termination of registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934 and the suspension of its duty to file reports under Sections 13 and 15(d). The Form 15 identifies the class of securities as common stock, par value $0.01 per share, and indicates reliance on Rule 12g-4(a)(1) and Rule 12h-3(b)(1)(i). This deregistration means Enzo is no longer an SEC-reporting public company, and its common stock is no longer listed or quoted on the NYSE or OTCQX.

Trading history and listing changes

Enzo’s recent history includes several notable listing and compliance events. In January 2025, the company announced it had received a notice of non-compliance from the New York Stock Exchange related to market capitalization, stockholders’ equity, and average closing stock price. In March 2025, Enzo announced its intention to voluntarily delist its common stock from the NYSE and to have its shares quoted on the OTCQX Best Market. The company stated that it would file a Form 25 with the SEC to effect the delisting, and that it expected trading on OTCQX to commence around mid-April 2025.

Subsequent disclosures confirm that the last day of trading of Enzo’s common stock on the NYSE was in April 2025 and that trading on OTCQX began shortly thereafter under the symbol ENZB. The August 20, 2025 8-K then reports that, as a result of the merger, the shares no longer trade on OTCQX or any other over-the-counter market.

Operational themes from recent disclosures

Across its recent financial and business updates, Enzo has highlighted several recurring themes:

• Focus on the Life Sciences division and life science tools following the sale of its clinical lab assets.
• Emphasis on drug development and cell and gene therapy market segments as drivers of revenue growth.
• Efforts to improve gross margins through product mix, cost containment initiatives, and removal of non-performing SKUs.
• Use of non-GAAP measures such as Adjusted net loss and Adjusted EBITDA to supplement GAAP results, with reconciliations provided in its releases.
• Attention to cash preservation, working capital management, and reduction of debt and certain liabilities.

Company status for investors and researchers

For investors researching the historical ENZ or ENZB stock, it is important to note that, based on the August 20, 2025 8-K and the Form 15-12G filed the same day, Enzo Biochem, Inc. is no longer a publicly traded, SEC-reporting company. The company continues to exist as a corporate entity but operates as a wholly owned subsidiary of Bethpage Parent, Inc. Historical information about Enzo’s operations, financial performance, and strategic shifts remains available through its prior SEC filings and press releases, which document its evolution from a broader diagnostics and clinical lab business toward a focused life sciences tools and technology company.